We are live on ! Find out more
VTYX

Ventyx Biosciences

Delisted

VTYX was delisted on the 3rd of March, 2026.

110 hedge funds and large institutions have $136M invested in Ventyx Biosciences in 2025 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 39 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

253% more call options, than puts

Call options by funds: $522K | Put options by funds: $148K

43% more capital invested

Capital invested by funds: $95.1M → $136M (+$41.3M)

0.94% less ownership

Funds ownership: 62.43%61.5% (-0.94%)

4% less funds holding

Funds holding: 114110 (-4)

17% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 23

21% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 39

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
110
Holders Change
-4
Holders Change %
-3.51%
% of All Funds
1.44%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
19
Increased
31
Reduced
39
Closed
23
Calls
$522K
Puts
$148K
Net Calls
+$374K
Net Calls Change
+$113K
Name Holding Trade Value Shares
Change
Change in
Stake
SFI
76
Susquehanna Fundamental Investments
Pennsylvania
$64.6K -$70.6K -26,630 -56%
Jacobs Levy Equity Management
77
Jacobs Levy Equity Management
New Jersey
$60.9K +$51.9K +19,577 New
Carson Wealth (CWM LLC)
78
Carson Wealth (CWM LLC)
Nebraska
$60K -$100K -37,866 -66%
Squarepoint
79
Squarepoint
New York
$51K -$223K -84,251 -84%
PAP
80
Persistent Asset Partners
Hong Kong
$50.7K +$43.2K +16,295 New
Fidelity Investments
81
Fidelity Investments
Massachusetts
$40.4K -$1.18K -444 -3%
AC
82
Avestar Capital
New York
$35.5K
AAP
83
Arax Advisory Partners
Colorado
$22.4K +$19.1K +7,203 New
TRCT
84
Tower Research Capital (TRC)
New York
$21.3K -$79.5K -29,992 -81%
FIA
85
FNY Investment Advisers
New York
$15K -$6.62K -2,500 -33%
Federated Hermes
86
Federated Hermes
Pennsylvania
$14.6K -$7.35K -2,774 -37%
ADL
87
Asset Dedication LLC
California
$13.4K
Russell Investments Group
88
Russell Investments Group
United Kingdom
$12.7K
PNC Financial Services Group
89
PNC Financial Services Group
Pennsylvania
$9.35K
Citigroup
90
Citigroup
New York
$7.69K -$116K -43,857 -95%
Barclays
91
Barclays
United Kingdom
$5.68K -$274K -103,571 -98%
TWD
92
True Wealth Design
Ohio
$5.33K -$1.77K -669 -28%
RA
93
Rise Advisors
New York
$2.71K
WANY
94
Wealthspire Advisors (New York)
New York
$2.63K +$2.24K +844 New
PWA
95
Physician Wealth Advisors
Utah
$2.59K
FFO
96
Fortitude Family Office
Arizona
$2.58K
Optiver Holding
97
Optiver Holding
Netherlands
$2.51K
CA
98
Clearstead Advisors
Ohio
$1.55K -$835 -315 -39%
Nisa Investment Advisors
99
Nisa Investment Advisors
Missouri
$1.5K
Royal Bank of Canada
100
Royal Bank of Canada
Ontario, Canada
$1K +$1.2K +453 +552%

VTYX Hedge Fund Activity: Q3 2025 in Review

110 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q3 2025, worth a combined $136M — up 43% from $95.1M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of VTYX and 19 opened new positions — a net loss of 4 holders — while 39 trimmed existing stakes and 31 added.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $2.71M. The largest seller was Point72 Asset Management, cutting an estimated $7.11M.

  • 110 institutional investors held Ventyx Biosciences (VTYX) as of Q3 2025, down from 114 in Q2 2025.
  • Funds reported $136M of Ventyx Biosciences stock for Q3 2025, up 43% quarter-over-quarter.
  • 19 funds opened new Ventyx Biosciences positions in Q3 2025 and 23 closed out, a net change of -4 holders.
  • The largest Ventyx Biosciences buyer in Q3 2025 was Baker Bros. Advisors, an estimated $2.71M added.
  • The largest Ventyx Biosciences seller in Q3 2025 was Point72 Asset Management, an estimated $7.11M sold.

Based on aggregated 13F filings for Q3 2025.